Baird served as joint-bookrunner on this offering.
AboutSarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) recently completed a follow-on offering of 2,102,000 shares of common stock at $17.84 per share, generating gross proceeds of approximately $37.5 million. The Company intends to use the net proceeds from the offering for product and commercial development, manufacturing, any business development activities and other general corporate purposes.
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. Applying its proprietary, highly-differentiated and innovative platform technologies, the Company is able to target a broad range of diseases and disorders through distinct RNA-targeted mechanisms of action. Sarepta Therapeutics is primarily focused on rapidly advancing the development of our potentially disease-modifying Duchenne muscular dystrophy (“DMD”) drug candidates, including our lead DMD product candidate, eteplirsen, designed to skip exon 51. On August 25, 2015, the Company announced the filing by the United States Food and Drug Administration (“FDA”) of its new drug application (“NDA”) for eteplirsen for the treatment of DMD amenable to exon 51 skipping. As of June 2016, Sarepta Therapeutics’ NDA for eteplirsen is still under review by the FDA. The Company is also developing therapeutics using its technology for the treatment of drug resistant bacteria and infectious, rare and other human diseases. Sarepta Therapeutics is based in Cambridge, Massachusetts.
For additional information about this transaction, please contact:
- June 2016
- Sarepta Therapeutics, Inc.
- Target Location
- North America